Thymic Tumor Clinical Trials (2026): 33 Recruiting Interventional Studies

Last updated: March 9, 2026

Current Clinical Trial Landscape

Recruiting Trials by Treatment Setting

First-Line / Newly Diagnosed

For previously untreated advanced or unresectable thymic tumors:

• NCT05832827 - Carboplatin/Paclitaxel + Lenvatinib + Pembrolizumab (first-line)
• NCT06730308 - Glucocorticoids + concurrent chemoradiotherapy for unresectable thymoma

Second-Line / Refractory

After progression on first-line therapy:

• NCT06838910 - Tislelizumab + Anlotinib (second-line)
• NCT03463460 - Pembrolizumab + Sunitinib (refractory)
• NCT05104736 - PT-112 novel agent
• NCT03295227 - Pembrolizumab monotherapy (unresectable)

Adjuvant / Post-Surgery

After surgical resection to reduce recurrence:

• NCT02633553 - Adjuvant radiotherapy for stage II/III thymoma after complete resection
• NCT06311955 - Postoperative carbon ion radiotherapy for residual disease
• NCT06311968 - Postoperative proton radiotherapy
• NCT06402708 - Postoperative adjuvant chemotherapy for thymic cancer

Neoadjuvant / Pre-Surgery

• NCT06924619 - Neoadjuvant radiotherapy for locally advanced unresectable thymoma

Trials by Treatment Approach

Radiotherapy (14 trials)

Proton therapy and carbon ion radiotherapy offer precise tumor targeting with less damage to surrounding tissue. View all →

Chemotherapy (8 trials)

Platinum-based combinations remain a backbone of treatment for advanced disease. View all →

Checkpoint Inhibitors (4 trials)

PD-1 inhibitors show activity but require careful monitoring due to autoimmune risks (myasthenia gravis). View all →

Trial listings from ClinicalTrials.gov. Page summaries generated by AI and may contain errors. Always verify with your healthcare provider.